Atopiclair.
BACKGROUND
MAS063DP cream has received marketing authorization in the USA and the EU as a medical device for the relief of symptoms of atopic dermatitis (AD) and contact dermatitis.


OBJECTIVE
Review of technical and clinical data in the literature on MAS063DP to evaluate the role that MAS063DP (Sinclair Pharmaceuticals Ltd) holds in the management of patients affected by AD.


METHODS
We explored the characteristics and efficacy of the product by a wide-ranging search of the medical and scientific studies in the literature and drew our conclusions also on the basis of our medical practice and knowledge concerning the treatment guidelines and therapy options of AD.


CONCLUSIONS
MAS063DP is a product dermatologists could enroll in the treatment of signs and symptoms of mild-to-moderate AD in adult and pediatric patients.
Patrizi
A
A
Division of Dermatology, Department of Internal Medicine, Geriatrics and Nephrologic Diseases, University of Bologna, Italy. annalisa.patrizi@unibo.it
Raone
B
B
Neri
I
I
D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D003877:Dermatitis, Contact / Q000188:drug therapy*; D004041:Dietary Fats / Q000627:therapeutic use*; D006034:Glycyrrhetinic Acid / Q000627:therapeutic use*; D006801:Humans; D010936:Plant Extracts / Q000627:therapeutic use*
D004041:Dietary Fats; C530270:MAS063DP; D010936:Plant Extracts; D006034:Glycyrrhetinic Acid